on behalf of the APEX Investigators* Background--Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.
only those events that are either fatal or result in irreversible cell death or harm to the patient. The present study is a post hoc analysis of the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study), which evaluates net clinical outcomes by comparing a composite of fatal or irreversible efficacy and safety events in patients treated with extended-duration betrixaban versus standard dosing enoxaparin for venous thromboembolism prevention among acute medically ill hospitalized patients. This article expands on the primary results of APEX, which assessed efficacy and safety end points independently. Additionally, the end point evaluated in this study includes only symptomatic events and therefore could be assessed in the modified intent-to-treat population, as opposed to the primary efficacy outcome population, which was used for the primary results.
Methods Study Design and Population
APEX was a randomized, double-blind, double-dummy, activecontrolled, multinational phase 3 clinical trial. The trial design and main results have been previously published. 1, 2 In brief, acutely medically ill men and women, 40 years or older, with reduced mobility and increased risk for venous thromboembolism hospitalized for either acute heart failure, respiratory failure, infectious disease, rheumatic disease, or ischemic stroke were eligible for enrollment. Major exclusion criteria were active bleeding or a high risk of bleeding, severe renal insufficiency with creatinine clearance <15 mL/min, or any condition requiring prolonged anticoagulation or antiplatelet therapy.
Patients were randomly assigned in a 1:1 ratio to receive either standard-duration subcutaneous enoxaparin 40 mg once daily for 10AE4 days plus oral betrixaban placebo once daily for 35 to 42 days or subcutaneous enoxaparin placebo once daily for 10AE4 days plus active extended-duration oral betrixaban (loading dose of 160 mg for the first dose followed by 80 mg once daily for 35-42 days). The dose of study drug was adjusted to 40 mg among patients with renal insufficiency with creatinine clearance <30 mL/min (both enoxaparin and betrixaban doses were halved) and patients receiving concomitant strong P-glycoprotein inhibitors (only betrixaban dose was halved). Clinical outcomes were assessed between day 35 and day 42 and again at an additional 30AE5 days after day 42. The modified intent-totreat cohort was used, which included all randomized patients who had at least one dose of study drug. The primary and first cohort tested (cohort 1) included patients who had positive D-dimer results (≥2 times the upper limit of normal) by local laboratory assessment. Cohort 2 included patients who had positive D-dimer results or were 75 years and older. In addition, end points were assessed in all randomized patients ( Figures S1 and S2 ). The study was approved by the local institutional review committees, and all enrolled participants provided informed consent.
End Points
All safety and efficacy end points were adjudicated by members of a clinical events committee blinded to study group assignment. In this post hoc analysis, the primary end point was the composite of all fatal or irreversible ischemic and bleeding events. This composite end point was previously used in the clinical trial assessment of prasugrel. 3, 4 An irreversible efficacy end point was defined as death from ischemic cerebral or cardiopulmonary causes, including ischemic stroke, fatal arrhythmias, heart failure, venous thromboembolism, and sudden death from unknown causes, as well as nonfatal events that resulted in necrosis of tissue including nonfatal myocardial infarction (MI), nonfatal pulmonary embolism (PE), and nonfatal ischemic stroke. An irreversible safety end point was defined as fatal bleeding or intracranial hemorrhage. Nonfatal PE was not included as an outcome in sensitivity analysis because some patients with PE do not have necrosis of lung tissue.
Statistical Analysis
In the analysis of the 80-and 40-mg dose cohorts, the actual dose the patient was treated with was used. All statistical analyses were programmed independently by two statisticians using SAS version 9.4 (SAS Institute Inc). Characteristics of the study population were evaluated using descriptive statistics. Data were expressed as frequencies and percentages for categorical variables, with denominators including all patients with available data. A time-to-first event survival analysis with right censorship was performed using a Cox proportional hazards regression model, where event rates were expressed as Kaplan-Meier estimates, and P values
Clinical Perspective
What Is New?
• Among hospitalized medically ill patients through 77 days of follow-up, 1 fatal or irreversible event could be prevented by treating 65 patients with extended-duration betrixaban compared with standard-of-care enoxaparin.
What Are the Clinical Implications?
• Extended-duration thromboprophylaxis using an experimental oral factor Xa inhibitor may reduce the risk of fatal or irreversible events among hospitalized medically ill patients.
were reported using the log-rank test. Events were analyzed through visit 3 or day 42 to reflect the primary analysis and through end of study at day 77 as an exploratory assessment. All events (efficacy or safety) were considered to have equal statistical weight. A P<0.05 was considered statistically significant.
Results
The baseline characteristics of the two cohorts were well matched. 2 The median time overall on enoxaparin/enoxaparin placebo and betrixaban/betrixaban placebo was 9 (interquartile range, 7-13) and 36 (interquartile range, 34-39) days, respectively. *Data for safety outcomes were evaluated through visit 3 or day 42. The breakdown of events adds up to more than the composite events because the composite includes only the first event the patient experienced. Modified intention-to-treat population for cohort 1 and cohort 2 analyses. † Enoxaparin was administered for 10AE4 days, followed by oral betrixaban placebo for 35 to 42 days. ‡ Includes fatal pulmonary embolism/venous thromboembolism-confirmed, fatal pulmonary embolism/venous thromboembolism-possible, fatal pulmonary embolism/venous thromboembolism-probable, arrhythmic event, heart failure, fatal ischemic stroke, fatal myocardial infarction (MI), and sudden death of unknown cause.
Composite event rates were consistently lower in the betrixaban arm across all cohorts, including and excluding nonfatal PE (Tables 1 and 2 ). In cohort 1 (patients with positive D-dimer results), there was a significant reduction in fatal or irreversible events at both visit 3 (35-42 days) and visit 4 (77 days) ( Figure 1 P=0.007) in favor of betrixaban over enoxaparin. Given the significant results in cohort 2, cohort 3 (all randomized patients) was therefore tested and also demonstrated a significant reduction in fatal or irreversible events ( Figure 2 ) in favor of betrixaban over enoxaparin. The number needed to treat to prevent 1 efficacy event was 65 when comparing betrixaban versus enoxaparin in all randomized patients through the end of the study. Betrixaban did not show higher risk for safety events from the composite when compared with enoxaparin, thus the number needed to harm could not be calculated. In all analyses, the improvement in net clinical outcomes began to emerge during the parenteral period of therapy. In a sensitivity analysis, which excluded nonfatal PE from the composite end point, betrixaban administration was associated with a similar reduction in the risk of the other fatal or irreversible events, which reached statistical significance at 77 days, end of study (Figures S3 and S4) . In addition, in a sensitivity analysis excluding nonfatal . As a sensitivity analysis, the data were analyzed using the Cochran-MantelHaenszel test, which also yielded a significant event reduction across all cohorts of patients and time windows (Table S1 ). In addition, a sensitivity analysis that replaced cardiopulmonary death with all-cause mortality showed no significant benefit across all cohorts through visit 3 and the end of the study (Table S2) .
In a series of similar analyses limited to patients receiving the full dose of betrixaban (80 mg), there was a consistent reduction in fatal or irreversible events as compared with enoxaparin (Table S3) . Fatal or irreversible events were significantly reduced in both cohort 1 and all randomized patients ( Figure 3 and Figure S5 ). In the smaller group of patients treated with the adjusted dose of betrixaban (40 mg), there was no significant reduction in events versus enoxaparin (Table S4 and Figure S6 ).
Of the 6 patients in the enoxaparin arm who experienced intracranial hemorrhages, 3 occurred while receiving enoxaparin and the remaining occurred while receiving either betrixaban placebo or no drug at all. No patients had renal insufficiency, and 5 of the 6 patients had creatinine clearances ≥60, while one had a clearance 30 to <60.
There was a significant reduction in the incidence of the traditional cardiovascular triple end point of cardiovascular death, MI, and all-cause stroke with extended-duration betrixaban versus standard duration enoxaparin in all randomized patients through visit 3 and visit 4. There was a 27% reduction in relative risk at visit 3 (2.29% versus 3.14%, P=0.023) and 25% at visit 4 (2.98% versus 3.97%, P=0.002) ( Figure S7 ).
Discussion
Assessment of net clinical outcome, the combined impact of efficacy and safety data, is a commonly requested evaluation on the part of healthcare providers, payers, and regulators. The decision to administer an agent is a binary decision (either yes or no), and safety and efficacy in making such a decision must both be considered simultaneously. In many analyses, reversible bleeding events with no permanent sequelae are combined with intracranial hemorrhage and fatal bleeding, which cause irreversible harm. Some analyses rely on a time-to-first bleeding event methodology. In such analyses, if the first event is minor, it may obscure the clinical impact of a later event associated with fatal or irreversible harm. As a relevant precedent, the Food and Drug Administration approved prasugrel based on its reduction of fatal and irreversible events related to either ischemia end points for efficacy or bleeding for safety and *End of trial defined as final follow-up visit (30+5 days after visit 3). Enoxaparin was administered for 10AE4 days, followed by oral betrixaban placebo for 35 to 42 days. ARR indicates absolute risk reduction; HR, hazard ratio; NNT, number needed to treat.
published their method to focus on fatal and irreversible events. 3 Based on this important precedent, we adopted a similar approach. The present study assessed outcomes during a relatively short period of %2 months. If similar risk reductions were maintained over a longer duration of followup, greater absolute risk reductions may have been observed. This post hoc analysis of APEX demonstrates that extended-duration betrixaban is associated with a significant reduction in fatal or irreversible events as compared with standard-duration enoxaparin. The benefit begins to emerge during the period of parenteral therapy and increases through the period of active treatment at 35 to 42 days as well as the entire duration of follow-up at 77 days. Based on the data from all randomized patients, one would need to treat 65 patients with betrixaban to prevent 1 fatal or irreversible event as compared with enoxaparin. In general, a number needed to treat <100 is considered compelling in clinical practice.
In a traditional net clinical outcomes analysis where efficacy events (including reversible and nonfatal efficacy events such as a positive compression ultrasound for asymptomatic proximal venous thromboembolism) are combined with major bleeding events (many of which are reversible and nonfatal), there is also a benefit in favor of betrixaban.
2 Because major bleeding was not increased with betrixaban, the net benefit associated with the drug is predominantly driven by its improved efficacy. However, a numeric but not significant excess of intracranial hemorrhages in the enoxaparin strategy helped drive the net clinical outcome in favor of betrixaban.
There was a significant reduction in fatal or irreversible events in cohort 1. The full dose of betrixaban (80 mg) was associated with a reduction in fatal or irreversible events, whereas the adjusted dose (40 mg) was not. Furthermore, in patients treated with the full 80-mg dose in cohort 1, there was a robust 2.3% absolute risk reduction (P=0.002), indicating that only 43 patients with positive D-dimer results in cohort 1 would need to be treated with full-dose betrixaban to prevent 1 fatal or irreversible event.
Findings from the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial 5 demonstrated a reduction in the primary end point, this was offset by an increase in fatal bleeding (7 fatal bleeds versus 1 fatal bleed, P<0.034) and an increase in intracranial hemorrhage (2 versus 0, P<0.25), making it difficult to demonstrate a favorable reduction in fatal or irreversible events. Neither ADOPT nor MAGELLAN published analyses of fatal or irreversible end points. It is notable that death, MI, and stroke, a combined end point often used in "arterial" cardiovascular trials, was reduced in acutely ill medical patients treated with betrixaban, a treatment, which was aimed at reducing "venous" thromboses events.
Limitations
The case report forms did not characterize whether the recurrent MIs were ST-segment elevation myocardial infarctions or non-ST-segment elevation myocardial infarctions, and infarct size of the recurrent MIs was not quantitated. In addition, adjudication was not performed to determine whether there was a segmental versus subsegmental involvement among patients with PE. Finally, this analysis did not use weighted outcomes to incorporate physician and patient preference regarding their perceived import regarding the outcomes.
Conclusions
Among hospitalized medically ill patients, extended-duration betrixaban demonstrates a favorable net clinical outcome and is associated with an %30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin followed by placebo. A total of 65 patients would require treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin.
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